Aducanumab Opinion
نویسندگان
چکیده
Aducanumab (brand name Aduhelm) is the first FDA-approved, pharmacologic treatment for Alzheimer’s disease (AD) but many uncertainties remain regarding both efficacy and safety. Of paramount concern are associated adverse effects including cerebral edema hemorrhage which prompted a post-approval study. Aside from safety concerns, withdrawal market may occur if it fails to demonstrate as described in pre-approval reports.
منابع مشابه
Opinion Opinion Opinion
A common notion of vision, consistent with this excerpt from the first paragraph of David Marr’s seminal book [1], is gained by considering the predicament of a person with a searchlight placed in a pitch-dark room full of unfamiliar furniture. One would hope that, by swinging the beam around, the observer will be able to recognize the objects present in the room (a cat here, an aquarium there,...
متن کاملPredicting Opinion Dependency Relations for Opinion Analysis
Syntactic structures have been good features for opinion analysis, but it is not easy to use them. To find these features by supervised learning methods, correct syntactic labels are indispensible. Two possible sources to acquire syntactic structures are parsing trees and dependency trees. For the annotation processing, parsing trees are more readable for annotators, while dependency trees are ...
متن کاملExplaining opinion polarisation with opinion copulas
An empirically founded and widely established driving force in opinion dynamics is homophily i.e. the tendency of "birds of a feather" to "flock together". The closer our opinions are the more likely it is that we will interact and converge. Models using these assumptions are called bounded confidence models (BCM) as they assume a tolerance threshold after which interaction is unlikely. They ar...
متن کاملBiogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
In the Phase 1b LTE, the most commonly reported adverse events were headache, fall and amyloid-related imaging abnormalit ies (ARIA). Of the 185 patients dosed with aducanumab in the Phase 1b study, 46 patients experienced ARIA-E (edema). There were no new cases of ARIA-E in patients who continued on the same dose of aducanumab. The incidence of ARIA-E in patients switching from placebo to aduc...
متن کاملOpinion: Yes
Nowadays, synthetic meshes are widely used in reconstructive surgeries of the pelvic floor. However, since the publication of the FDA warning about associated complications in 2011 (1), several discussions and contrary opinions have been published about its usefulness. The fear of court lawsuits related to side effects, common in some settings, has contributed to the widening of global discussi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International journal of medical science and clinical research studies
سال: 2022
ISSN: ['2767-8326', '2767-8342']
DOI: https://doi.org/10.47191/ijmscrs/v2-i8-12